World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
65
Citations
17045
World Ranking
2490
National Ranking
1010

Richard Haubrich publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Richard Haubrich sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 200 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Richard Haubrich D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Richard Haubrich sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 65 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Richard Haubrich is affiliated with the University of California, San Diego in the United States. Their research primarily focuses on medicine, with particular attention to infectious diseases, virology, neurology, emergency medicine, and epidemiology. The bulk of their scientific contributions are concentrated in infectious diseases, where they have published extensively.

The main topics covered in Richard Haubrich's research include:

  • HIV/AIDS drug development and treatment
  • COVID-19 clinical research studies
  • HIV research and treatment
  • HIV/AIDS research and interventions
  • Long-term effects of COVID-19
  • HIV-related health complications and treatments
  • SARS-CoV-2 and COVID-19 research

Their recent papers include the following:

  • "Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care" (2020), published in Clinical Infectious Diseases
  • "Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort" (2021), published in Clinical Infectious Diseases
  • "Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial" (2021), published in Infectious Diseases and Therapy
  • "Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality" (2021), published in Open Forum Infectious Diseases
  • "Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age" (2022), published in HIV Medicine

Among frequent co-authors collaborating with Richard Haubrich are:

  • Essy Mozaffari
  • Mark Thrun
  • Robert Gottlieb
  • Aastha Chandak
  • Paul Hodgkins

The researcher's work has appeared in a variety of publication venues, with multiple papers published in the following journals and repositories:

  • UNC Libraries
  • Open Forum Infectious Diseases
  • Clinical Infectious Diseases
  • Value in Health
  • HIV Medicine

Best Publications

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter

    Scott M. Hammer;David A. Katzenstein;Michael D. Hughes;Holly Gundacker

  • Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

    Sharon A. Riddler;Richard Haubrich;A. Gregory DiRienzo;Lynne Peeples

  • The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.

    Haubrich Rh;Little Sj;Currier Js;Forthal Dn

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy

    Miguel Goicoechea;Shanshan Liu;Brookie Best;Shelly Sun

  • Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

    Richard H. Haubrich;Sharon A. Riddler;A. Gregory DiRienzo;Lauren Komarow

  • Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

    Robert W. Shafer;Laura M. Smeaton;Gregory K. Robbins;Victor De Gruttola

  • Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems

    Mari M Kitahata;Benigno Rodriguez;Richard Haubrich;Stephen Boswell

  • Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

    Christine Katlama;Richard Haubrich;Jacob Lalezari;Adriano Lazzarin

  • Therapeutic drug monitoring in HIV infection: current status and future directions.

    David J. Back;Giorgio Gatti;Courtney Fletcher;Rodolphe Garaffo

  • Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection

    Takuya Yamamoto;David A. Price;David A. Price;Joseph P. Casazza;Guido Ferrari

  • Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP.

    Jill Blumenthal;Sonia Jain;Douglas Krakower;Xiaoying Sun

  • Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection.

    Kristin L. Boswell;Robert Paris;Eli Boritz;David Ambrozak

  • HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins

    Zabrina L. Brumme;Zabrina L. Brumme;Mina John;Jonathan M. Carlson;Chanson J. Brumme

  • Effect of Influenza Vaccination on Viral Replication and Immune Response in Persons Infected with Human Immunodeficiency Virus Receiving Potent Antiretroviral Therapy

    Huldrych F. Günthard;Huldrych F. Günthard;Joseph K. Wong;Joseph K. Wong;Celsa A. Spina;Celsa A. Spina;Caroline Ignacio

  • Identification of Patients with Acute AIDS-Associated Cryptococcal Meningitis Who Can Be Effectively Treated with Fluconazole: The Role of Antifungal Susceptibility Testing

    Mallory D. Witt;Roger J. Lewis;Robert A. Larsen;Eric N. Milefchik

  • Dynamics of Total, Linear Nonintegrated, and Integrated HIV-1 DNA In Vivo and In Vitro

    Kersten K. Koelsch;Lin Liu;Richard Haubrich;Susanne May

Frequent Co-Authors

Douglas D. Richman
Douglas D. Richman University of California, San Diego
Eric S. Daar
Eric S. Daar Lundquist Institute
Davey M. Smith
Davey M. Smith University of California, San Diego
Roy M. Gulick
Roy M. Gulick Cornell University
Mina John
Mina John Royal Perth Hospital
Simon Mallal
Simon Mallal Vanderbilt University Medical Center
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
David W. Haas
David W. Haas Vanderbilt University Medical Center
J. Allen McCutchan
J. Allen McCutchan University of California, San Diego
Susan J. Little
Susan J. Little University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to various related fields, many of which can be pursued through flexible online programs. For instance, students interested in public health can explore online public health masters programs easy to get into, allowing a smooth transition into vital community health roles without overly competitive admission processes.

Beyond microbiology, healthcare careers such as becoming a child life specialist salary also attract graduates. This role involves supporting children and families in medical environments, making it a rewarding choice with competitive financial prospects.

Additionally, many online degrees cater to individuals with diverse backgrounds; what is the best degree for a convicted felon guides those seeking career opportunities despite past challenges, highlighting accessible programs that foster new beginnings.

For those inclined towards holistic healthcare, careers like a functional medicine nurse salary offer promising paths combining traditional nursing with alternative practices, often supported by targeted online education options.

Best Scientists Citing Richard Haubrich

Trending Scientists

Recently Published Articles